A genetic deficiency of adenosine deaminase (adenosine aminohydrolase, EC 3.5.4.4) produces combined immunodeficiency disease in humans (1) . The profound lymphopenia observed in affected children has been attributed to the toxic effects of deoxyadenosine (2) (3) (4) (5) (6) (7) . These findings have prompted the development of adenosine deaminase inhibitors and deoxyadenosine congeners resistant to deamination, in the hope that these agents might possess antileukemic and antilymphocyte activity (8, 9) .
Several studies have now shown that the high-affinity adenosine deaminase inhibitor deoxycoformycin can increase plasma deoxyadenosine levels in patients with malignant disease, with resulting toxicity to normal and neoplastic lymphocytes (10) (11) (12) (13) (14) (15) (16) . In an earlier study, we identified a deoxyadenosine congener, 2-chloro-2'-deoxyadenosine (CdA; see Fig. 1 ) (17) , that was toxic to human lymphoblastoid cell lines at concentrations in the nanomolar range (8) . The CdA was not deaminated significantly, but instead was actively phosphorylated by deoxycytidine kinase (EC 2.7.1.74), converted to the 5'-triphosphate derivative, and incorporated into DNA (8, 18) . The CdA was also an effective agent for the treatment of murine L1210 lymphoid leukemia in vivo (18) . Notably, in vitro it was exquisitely toxic to normal resting peripheral blood lymphocytes and to slowly dividing malignant T cells. This ability to kill nondividing lymphocytes distinguished CdA from other commonly used chemotherapeutic agents affecting purine and pyrimidine metabolism (18, 19) . We also tested the anti-proliferative effects of CdA toward more than 40 bone marrow specimens from patients with acute leukemia, as compared to 20 normal bone marrow specimens (18) . The deoxynucleoside inhibited the proliferation and survival of many leukemia cells at concentrations that did not significantly impair spontaneous thymidine uptake or granulocyte-monocyte colony formation by normal bone marrow cells.
On the basis of (i) the marked toxicity of CdA toward many human malignant hematologic cell lines but not toward cell lines derived from solid tissues, (ii) the efficacy of the drug in the L1210 leukemia system, and (iii) the toxicity of the deoxynucleoside toward fresh human leukemia cells at concentrations that did not similarly suppress bone marrow colony formation, we initiated CdA toxicity studies in primates and a Phase I clinical trial in patients with intractable hematologic malignancies. The results of these investigations indicate that the deoxyadenosine analog has significant antileukemic and immunosuppressive activity.
MATERIALS AND METHODS
Synthesis of CdA. CdA was prepared as a single lot by transfer of the deoxyribose moiety from thymidine to 2-chloroadenine, catalyzed by a partially purified transdeoxyribosylase from Lactobacillus helveticus (8, 18) . The drug was isolated by ion-exchange chromatography as described (18) with other purine bases or nucleosides. When autologous pretreatment plasma was used as a diluent, the radioimmunoassay detected CdA at concentrations -5 nM.
In general, increasing dosages of CdA given via continuous intravenous infusion yielded increasing plasma concentrations. For uncertain reasons that may relate to baseline renal tubular function or to tumor burden, the plasma levels varied up to 3-fold among patients who received the same dosage. In each subject, the plasma CdA concentrations rose gradually during the drug infusion. At the time of rapid tumor cell lysis, plasma CdA levels increased abruptly (Fig. 3 Upper). With termination of the CdA infusion, the nucleoside was cleared from the plasma over a period of 1-3 days.
The fractionation of deproteinized plasma from CdA-treated patients by high-performance liquid chromatography revealed primarily CdA, with lesser amounts of 2-chloroadenine (results not shown). Chromatographic analysis of spot urine specimens taken during treatment yielded basically similar results. No deaminated products of the drug were detected.
Antileukemic and Immunosuppressive Effects of CdA. Nine patients with far advanced hematologic malignancies received CdA at 0.1-1.0 mg/kg per day by continuous intravenous infusion for 4-14 days (Table 1 ). The drug was well tolerated. Only the patient who received the highest dosage experienced significant nausea and vomiting during the infusion. None had drug-related fevers or changes in sensorium.
Several of the patients who participated in the protocol had received prior chemotherapy with cytosine arabinonucleoside. As illustrated in Fig. 3 Lower, leukemic cells resistant to cytosine arabinonucleoside remained sensitive to the in vitro toxic effects of CdA.
In all patients with leukemia, the CdA lowered the peripheral blood blast count by at least 50%. Responses were observed at various dosages from 0.1 to 1.0 mg/kg per day. In one patient with a refractory T-cell leukemia-lymphoma and in one patient with chronic myelogenous leukemia in blast crisis the CdA eliminated detectable malignant cells from the blood and bone marrow (Fig. 3 Upper) . Unfortunately, both The patient was discharged from the hospital, but remained persistently thrombocytopenic and ultimately succumbed from a second cerebrovascular accident occurring several months after the discontinuation of chemotherapy. An autopsy could not be performed.
Toxicity of CdA in Humans. Bone marrow suppression was the dose-limiting toxicity. Some degree of leukopenia, thrombocytopenia, or both was observed in all patients who received CdA at a dose of at least 0.2 mg/kg per day for 5 days ( Table 1 ). The degree of bone marrow suppression was related not only to the rate of administration but also to the cumulative dosage and to the tumor burden at the start of chemotherapy.
Three patients had mild and transient increases of serum glutamic-oxaloacetic transaminase during the CdA infusion.
All three had abnormal liver function tests prior to treatment. CdA did not induce significant changes in serum urea nitrogen or creatinine.
DISCUSSION
The present studies document the antileukemic and immunosuppressive properties of CdA. This adenosine deaminaseresistant deoxyadenosine analog was administered by continuous intravenous infusion to nine patients with advanced hematologic malignancies refractory to conventional chemotherapy. The CdA infusions were well tolerated clinically. In all the leukemia patients, the drug lowered the number of circulating blasts. In one patient with a T-cell leukemia-lymphoma, and in one patient with chronic myelogenous leukemia in blast crisis, the CdA eliminated detectable blasts from the blood and bone marrow. In a patient with advanced lymphoma, the treatment halted a severe autoimmune hemolytic process.
Bone marrow suppression represented the dose-limiting toxic effect of the deoxynucleoside. Leukopenia, thrombocytopenia, or both occurred in all patients who received 0.2 mg/kg per day for at least 5 days. Such dosages usually produced plasma CdA levels .20 nM as measured by radioimmunoassay. These results are consistent with previous in vitro studies, in which similar CdA concentrations inhibited spontaneous thymidine uptake and granulocyte-monocyte colony formation by normal human bone marrow cells (18) .
The continuous administration of CdA for several days at even modest dosages (0.1-0.2 mg/kg per day) induced the lysis of susceptible hematologic neoplasms. Accompanying tumor destruction was a sudden increase in plasma CdA to concentrations capable of causing sustained bone marrow suppression. The synchronous discharge and subsequent dephosphorylation in the plasma of CdA 5'-phosphates, previously trapped in the tumor cells, offers a plausible explanation for the phenomenon. The predicament might be averted by vigorous cytoreduction with conventional chemotherapeutic agents prior to, or concurrent with, treatment.
Although analogs of deoxyadenosine are more toxic to lymphocytes than to other cell types, they can potentially harm all normal somatic cells. In this regard, the high-affinity adenosine deaminase inhibitor deoxycoformycin has demonstrated considerable chemotherapeutic activity against leukemias and lymphomas but has produced idiosyncratic and sometimes unacceptable damage to normal tissues (10) (11) (12) (13) (14) (15) (16) . The toxicity correlated with sustained increases in the plasma concentrations of endogenously generated deoxyadenosine and adenosine. With CdA, as opposed to deoxycoformycin, the chemotherapist can more easily regulate the plasma levels of the active deoxynucleoside moiety. Conceivably, the toxicity of CdA toward normal cells could be reduced by altering the mode or schedule of administration.
Among human malignant lymphoblastoid cell lines, resistance to CdA is achieved easily by a change in the nucleoside transport system, the loss of deoxycytidine kinase, or an increase in the endogenous synthetic rate of deoxynucleosides (ref. 21 and unpublished data). In particular, the latter event may require only a single dominantly inherited metabolic alteration and does not impair cell growth. These same changes also render malignant cells resistant to the antiproliferative effects of cytosine arabinonucleoside. As shown here, and also in our earlier study (18) , leukemic cells clinically resistant to cytosine arabinonucleoside often remain sensitive to CdA. Besides CdA, other deoxynucleosides active in the L1210 mouse leukemia model include the 2-fluoro and 2-bromo derivatives of deoxyadenosine, and 9-f3-D-arabinofuranosyl-2-fluoroadenine (9, (22) (23) (24) . On a molar basis, CdA is the most potent of these agents in vitro. Although the metabolisms of the various deoxyadenosine congeners are basically similar, the exact modes of action, pharmacokinetics, and potential toxic effects of the drugs may differ. Thus, the results of the present in vivo trial may not apply to these other potentially promising antileukemic agents.
The accumulated data suggest that CdA possesses the following favorable chemotherapeutic properties: (i) antileukemic and immunosuppressive activity, (ii) high degree of patient compliance, (iii) resistance to deamination, (iv) relative selectivity toward malignant lymphocytes and hematologic cells, and (v) ability to kill cells arrested in prolonged G1 phase. However, the agent may depress bone marrow function, trigger sudden tumor lysis, and engender early drug resistance.
